Overview

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Status:
Recruiting
Trial end date:
2033-12-31
Target enrollment:
Participant gender:
Summary
Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for standard risk acute lymphoblastic leukemia in children and adolescents.
Phase:
Phase 2
Details
Lead Sponsor:
Hee Young Ju
Treatments:
Asparaginase
BB 1101
Cyclophosphamide
Cytarabine
Dexamethasone
Dexamethasone acetate
Doxorubicin
Liposomal doxorubicin
Mercaptopurine
Methotrexate
Vincristine